Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) shares traded down 3.7% during trading on Tuesday . The company traded as low as $20.09 and last traded at $20.02. 32,205 shares traded hands during trading, a decline of 96% from the average session volume of 867,794 shares. The stock had previously closed at $20.78.
Analyst Upgrades and Downgrades
CLDX has been the topic of several recent analyst reports. The Goldman Sachs Group reduced their price target on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. UBS Group initiated coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $44.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Friday, February 28th. Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Finally, Morgan Stanley started coverage on shares of Celldex Therapeutics in a research note on Thursday, March 20th. They issued an "overweight" rating and a $46.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Celldex Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $54.33.
Check Out Our Latest Stock Report on Celldex Therapeutics
Celldex Therapeutics Price Performance
The company has a market capitalization of $1.32 billion, a PE ratio of -7.75 and a beta of 1.76. The company's fifty day moving average is $21.90 and its 200-day moving average is $26.44.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. The business had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Equities research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.
Institutional Trading of Celldex Therapeutics
Hedge funds have recently modified their holdings of the company. Deep Track Capital LP purchased a new position in shares of Celldex Therapeutics in the 4th quarter worth approximately $38,919,000. Wellington Management Group LLP boosted its stake in Celldex Therapeutics by 14.5% in the third quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock valued at $314,190,000 after acquiring an additional 1,167,659 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in Celldex Therapeutics by 50.8% in the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock worth $63,579,000 after purchasing an additional 847,264 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after purchasing an additional 676,771 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new position in Celldex Therapeutics during the 4th quarter valued at about $7,707,000.
About Celldex Therapeutics
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Further Reading
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
